Sunitinib appears to be an effective single-agent therapy for patients with recurrent non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1626, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

Erlotinib in non-small cell lung cancer: a review

By Blackhall Fiona H   Rehman Shazza   Thatcher Nicholas  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 995-1002

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

By Reckamp Karen L.   Koczywas Marianna   Cristea Mihaela C.   Dowell Jonathan E.   Wang He-Jing   Gardner Brian K.   Milne Ginger L.   Figlin Robert A.   Fishbein Michael C.   Elashoff Robert M.   Dubinett Steven M.  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

Blackwell Publishing

Access to resources Recommend Favorite

Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience

By >   >   >   >   Katz Artur  

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 207-216

Adis International

Access to resources Recommend Favorite